placebo-controlled trial – Communicable Diseases Research

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

Article

Published on 2022-12-012022-10-06
Journal: The Lancet Regional Health - Western Pacific
[Category] 진단,

Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial

Article

Published on 2022-11-032022-11-16
Journal: Journal of Translational Medicine
[Category] 비임상,

[키워드] 1:1 Administered administration adverse event age Analysis animal model Anti-inflammatory assigned baseline Borg change changes in Chronic diseases clinical trial clinically COVID COVID pneumonia COVID-19 defined Diagnosis discharged double-blind Dyspnea Effect effective Efficacy Endpoint enrolled evaluated female female gender FEV first symptom FVC impairment increase in indicated Infection initial LLC lung damage Lung fibrosis Lung function Lungs mMRC moderate NCT04527354 offer past medical history Patient patients pharmacological treatment Placebo placebo group placebo-controlled clinical trial placebo-controlled trial Post-COVID rehabilitation predicted Prevent Primary outcome proportion pulmonary dysfunction pulmonary fibrosis Pulmonary function questionnaire Randomized Randomly reduction in Registered rehabilitation risk factor Russia SARS-CoV-2 secondary shown significant decrease significant difference stratified Support Symptoms Tolerability Treamid. Treatment Trial was done women
[DOI] 10.1186/s12967-022-03660-9 PMC 바로가기

Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with Selected Lactobacilli in COVID-19 Outpatients

Article

Published on 2022-10-262022-11-15
Journal: Microbiology Spectrum
[Category] COVID19(2023년), SARS, 변종, 치료기술, 치료제,

[키워드] acting acute respiratory syndrome added Administered administration Amplicon sequencing analyses Analysis antibody Antiviral antiviral property antiviral strategy applied Bacteria benefit Care chills collected Combined coronavirus coronavirus disease COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients detectable Diagnosis diarrhea double-blind dried blood spot eligible evaluated Fever Health hospital Hospitalization infected with SARS-CoV-2 Lactobacillaceae lactobacilli Microbiome modulation multifactorial nasopharyngeal viral load nose-throat swab online questionnaire Outpatient Pain Patient per-protocol analysis Placebo placebo-controlled trial positive potential mechanism practitioners qPCR quantitative PCR Randomized reduce reducing reported reported symptom respiratory tract infection respiratory viral disease SARS-CoV-2 selected sequence severity significantly spray strain Symptom symptom resolution the patient the placebo group therapy Throat throat spray. Treatment Trial trials upper respiratory tract Vaccines variant Viral diseases viral infection Viral load was performed
[DOI] 10.1128/spectrum.01682-22 PMC 바로가기

Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19

Article

Published on 2022-10-192022-11-15
Journal: PLoS Medicine
[Category] COVID19(2023년), SARS, 치료제,

[키워드] 95% CI Administered administration Adverse affected analysed antiviral therapy Antiviral treatment ARMS baseline changed Combination combination therapy concentrations conducted coronavirus 2 COVID-19 COVID-19 pandemic Day Dose escalation doses double-blind double-blind trial drug level effective Efficacy evaluate the effect event Favipiravir healthy Interaction Lopinavir-ritonavir measure monotherapy Odds ratio Outpatient participant Participants Phase 2 Placebo placebo-controlled placebo-controlled trial placebos plasma primary analysis Primary outcome provided randomised recruited reduced respiratory SARS-CoV-2 SARS-CoV-2 viral load significant interaction significantly study population symptom onset the mean trajectory Treatment undetectable United Kingdom Viral load virus
[DOI] 10.1371/journal.pmed.1004120 PMC 바로가기

Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial

Randomized Controlled Trial

Published on 2022-10-012022-10-04
Journal: Journal of Clinical Virology
[Category] COVID19(2023년), SARS, 임상,

[키워드] absence Administered analysed Anti-spike clinical clinical symptom clinical trial co-morbidity Community Course COVID-19 COVID-19 pandemic double blind Effect Efficacy and safety eligibility criteria evaluate Evaluating healthcare Immunoglobulin Infection nasal offer participant Placebo placebo-controlled placebo-controlled trial positive primary end point Prophylactic Prophylaxis random randomised Randomised trial Randomized reduced Result Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2. significantly subject tested the primary endpoint the spike protein Treatment vaccination
[DOI] 10.1016/j.jcv.2022.105248 PMC 바로가기 [Article Type] Randomized Controlled Trial

Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial

Article

Published on 2022-09-172022-10-06
Journal: EClinicalMedicine
[Category] 진단,

[키워드] 1:1 95 % CI Activation addition Administered adverse event approach assigned Basel blockade BMI canakinumab Clinical outcome contributing to COVID-19 CRP Dexamethasone diabetes died dose double-blind dropped drug Efficacy foundation glycaemic control higher risk hospitalised Hospitalization Hyperinflammatory ICU IL-1beta IL-1β IL-6 IMPROVE Inflammasome innate immune system interleukin-1β intravenous dose less medication multicenter multicentre Novartis Obesitiy. obesity outcome participant Patient patients treated patients with COVID-19 Placebo placebo group placebo-controlled trial primary analysis randomised randomization Randomly reduction Registered reported required SARS-CoV2 SARS-CoV2 infection Science Seven severe COVID-19 significantly Standard-of-care statistically significant statistically significant difference survival Switzerland systemic inflammation tested treated Treatment type 2 diabete university Ventilation with COVID-19
[DOI] 10.1016/j.eclinm.2022.101649 PMC 바로가기 [Article Type] Article

A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID

Article

Published on 2022-09-152022-11-16
Journal: Trials
[Category] SARS, 변종,

[키워드] 1:1 applied carrageenan clinical trial COVID-19 COVID-19 infection COVID-19. demonstrated double-blind double-blinded Effect effective Efficacy expressed General population host cell surface host cells in vitro activity include Infection infections initial viral load iota-carrageenan kappa-carrageenan nasal Non-COVID-19 nose and throat occur outcome participant penetrate Placebo placebo-controlled placebo-controlled clinical trial placebo-controlled trial polysaccharide positive PCR Prophylactic Prophylaxis purified questionnaire randomised receptors reduce Research risk SARS-CoV-2 secondary Seroconversion severity severity of COVID-19 shown Sodium chloride Study protocol subsequent Swab Symptom symptom onset thought treatment arm Trial upper respiratory tract utility vaccination Vaccine variant viral entry virus
[DOI] 10.1186/s13063-022-06685-z PMC 바로가기

Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial

Article

Published on 2022-09-022022-10-06
Journal: The Lancet. Respiratory Medicine
[Category] 진단,

[키워드] 1:1 Activation adjusted odds ratio age analysis assigned block brensocatib clinical status common adverse event criteria death disorder dose double-blind enrolment enzyme hospital Hospital admission hospitalised IMPROVE in both group Infection infections inhibitor intention-to-treat population investigated investigator involved ISRCTN medication multicentre neutrophil Older outcome parallel-group participant pathogenesis of COVID-19 Patient patients Placebo placebo-controlled trial Primary outcome random random assignment randomised Randomly receive Registered reported required responsible risk factor safety population serine protease serine proteases severe disease stratified study drug supported the placebo group therapy Treatment Trial university web-based randomisation system were excluded WHO ordinal scale with COVID-19
[DOI] 10.1016/S2213-2600(22)00261-2 PMC 바로가기 [Article Type] Article

Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial

경증 COVID-19에서 입원으로의 진행을 예방하는 단일 용량 및 이중 용량 이버멕틴 조기 치료의 효능: 다군, 병렬 그룹, 무작위, 이중 맹검, 위약 대조 시험

Randomized Controlled Trial

Published on 2022-09-012022-09-11
Journal: Respirology (Carlton, Vic.)
[Category] COVID19(2023년), SARS, 임상, 치료제,

[키워드] absolute difference adverse event anti-parasitic Antiviral antiviral agent Clinical course clinical trial conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection dermatitis double-blind early treatment Efficacy enrolled evaluate Hospitalization hypertension investigated Ivermectin ivermectin group Mild mild COVID-19 mild COVID-19 patients Mild symptom mild symptoms multi-arm no significant difference parallel-group Patient Placebo placebo group placebo-controlled trial Primary outcome progression proportion proportions Randomized randomized clinical trial randomized clinical trial. receive required reverse transcription reverse transcription-PCR SARS-CoV-2 severity Severity Score Single-dose statistically significant subject Tachycardia
[DOI] 10.1111/resp.14318 PMC 바로가기 [Article Type] Randomized Controlled Trial

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

Randomized Controlled Trial

Published on 2022-09-012022-10-04
Journal: International Journal of Infectious Diseases
[Category] COVID19(2023년), SARS, 임상, 진단,

[키워드] administration adverse event antibody Casirivimab clinically conducted COVID-19 death defined demonstrated development dose doses double-blind Efficacy end point evaluate evaluated exploratory hypersensitivity reaction Imdevimab incidence of COVID-19 laboratory-confirmed monoclonal antibody occurred Occurrence occurrence of COVID-19 Odds ratio participant Placebo placebo-controlled trial Prevent proportion Randomized reaction reduction in Repeat reported risk reduction SARS-CoV-2 SARS-CoV-2. Seroconversion substantial risk Tolerability treatment period treatment-emergent adverse event uninfected volunteers
[DOI] 10.1016/j.ijid.2022.06.045 PMC 바로가기 [Article Type] Randomized Controlled Trial